More than just sweet by Pietschmann, C.
More than 
Just Sweet
When they hear the word sugar, the first thing most people think of is candy. Some may 
also think of diabetes. Peter H. Seeberger from the Max Planck Institute of Colloids 
and Interfaces in Golm, in contrast, wants to use sugars to develop more effective drugs 
and vaccines. He hopes his work will benefit primarily poorer countries.
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Photo-reactor for flow synthesis. This method 
involves piping the reactants through a 
coiled-up tube and irradiating them with light. 
Researchers can use it to produce a wide 
variety of chemical substances. P 
eter H. Seeberger has headed 
the Biomolecular Systems De-
partment at the Max Planck 
Institute of Colloids and In-
terfaces in Potsdam since 
2009. He is one of the protagonists in 
the field of glycomics – a branch of re-
search that is trying to get to the bot-
tom of the entire complement of natu-
ral sugar molecules. One of the ways in 
which Seeberger wants to use these 
molecules, which experts refer to as gly-
cans, is to learn how cells communicate 
with each other.
Chemically speaking, sugars are 
compounds that consist of longer or 
shorter, branched or linear chains of in-
dividual sugar building blocks. Some 80 
percent of plant biomass on Earth con-
sists of sugars, and the largest propor-
tion by far is made up of the cellulose 
of plant cell walls, a chain molecule 
made of glucose. 
But glycans don’t just provide plant 
cells with stability – they are also mo-
lecular antennae with which cells can 
make contact with the proteins of their 
“neighbors.” Each cell in a human, an-
imal or plant is downright littered with 
sugars on its surface. Like tiny anten-
nae, the sugar chains coupled to fats 
and proteins jut out from the surface of 
the cell. Bacteria and viruses also use 
these antennae to dock onto.
GLYCANS AS AN ADDRESS CODE  
Sugars are involved as early as the fer-
tilization of the egg cell. In the nascent 
embryo, glycans act as a kind of zip 
code and direct cells to their destina-
tion. “It’s interesting that precisely 
these sugars turn up again in later life,” 
says Seeberger. “When cancer cells mi-
grate and form metastases, the same 
address system is used again.” 
There are four classes of glycans. First 
the glycoproteins, proteins to which 
sugar chains are bound. About 75 per-
cent of the membrane proteins of hu-
man cells belong to this class. One (in-)
famous example is erythropoietin, ab-
breviated EPO. This messenger sub-
stance stimulates the growth of red 
blood cells, thus helping cancer pa-
tients with impaired blood formation 
– but also athletes who want to illegal-
ly improve their performance.  
The second class, the glycosamino-
glycans, includes heparin, a blood co-
agulation inhibitor used all the time in 
medicine. While its glycan chain con-
sists of 200 to 250 sugars, the sweet 









































































Technology (MIT) in Cambridge, con-
verted an old DNA synthesizer for this 
purpose. The sugar building blocks are 
linked together in a similar way to how 
the DNA building blocks are assem-
bled. Linkage molecules, which act like 
small eyelets, are bound to a substrate 
of plastic beads the size of grains of 
sand. The first sugar is attached to 
these. Its potential binding sites have 
protective molecules on them that can 
be split off. In the next step, the pro-
tective cover is removed from the in-
tended site. This is then followed by 
the next coupling step.
Attach, remove protective cap, at-
tach, remove protective cap – cycle by 
cycle, he succeeded in attaching one 
sugar to the next up to a “nine-fold 
sugar,” a polysaccharide made of nine 
is usually only five to six sugars long. 
The different blood groups, for exam-
ple, are based on these sugar-contain-
ing fats. The fourth group is comprised 
of compounds of fats and proteins with 
glycans, “GPI anchors.” They attach 
proteins in the cell membrane.
Glycans have a relatively simple 
structure compared with other mole-
cules. Back in the late 1800s, German 
chemist Emil Fischer decoded the 
structure of individual building blocks 
of sugar and received the Nobel Prize 
for this work in 1902. So why has it tak-
en so long to investigate the function 
of the glycans? “That’s easy to ex-
plain,” says Seeberger. “Until recently, 
there was no fast and reliable technol-
ogy with which we could analyze and 
artificially produce sugar chains.”
The glycans get their backbone from 
ring-shaped sugar building blocks, 
each consisting of four or five carbon 
atoms and one oxygen atom. Such 
rings have large numbers of binding 
sites. Their biological activity depends 
on whether two sugars are joined to-
gether at the correct position and with 
the correct physical structure. 
Nobody knows how many different 
glycans exist overall. And there is still 
a lot of speculation as to whether cer-
tain lengths or patterns occur again 
and again.
Though scientists were already able 
to multiply DNA in the 1970s, it was 
2001 before they were successful with 
the automatic synthesis of oligosaccha-
rides. Peter H. Seeberger, then a Profes-
sor at the Massachusetts Institute of 
Glycans have numerous roles in a cell: On proteins and fats of the cell membrane, they constitute important contact points with other cells. 
GPI anchors, on the other hand, attach proteins in the cell membrane. Glycosaminoglycans are chain molecules composed of repeating 





























sugar building blocks. The synthesizer 
shortens the time needed for the task 
from months to hours. The team has 
since further refined the method and 
produced more than fifty different sug-
ar building blocks for the machine. Ev-
ery cycle, every new link in the chain, 
takes around three hours. The research-
ers currently hold the world record: 
chains of thirty sugar building blocks.
The linkage molecules were a criti-
cal point, because at the end, the gly-
cans need to be split off from the plas-
tic substrate. The latest version is now 
a photosensitive molecule. 
There was only one problem here: 
light can’t penetrate into the plastic. 
But team member Daniel Kopetzki had 
already solved this problem in a differ-
ent research project, synthesizing the 
malaria drug artemisinin. To enable the 
light to really reach all molecules, 
Kopetzki wrapped a thin, transparent 
tube around a small, transparent, plas-
tic chip containing sixty LEDs and 
pumped the reaction solution into it. 
Using light intensity and pumping 
speed, the reaction could now be opti-
mally controlled – “flow synthesis” was 
born. “We can now make the yield of 
chemical reactions independent of the 
human factor – that is, the skill of the 
chemist,” emphasizes Seeberger. 
The diameter of the tube through 
which the sugar is pumped is hardly 
bigger than the substrate particles. So 
each linkage molecule really does re-
ceive sufficient light and can release the 
sugar chains attached to the substrate. 
VACCINES MADE FROM SUGAR 
There are currently six sugar synthesiz-
ers in the world, four of them in Berlin. 
Seeberger’s team uses them in conjunc-
tion with the flow reactors for various 
purposes. The 75 team members in-
clude immunologists and parasitolo-
gists, in addition to chemists, biochem-
ists and engineers, because one focus of 
Seeberger’s research is vaccines made 
from glycans.
Three sugar-based vaccines against 
bacterial infections have already been 
developed using traditional methods: 
vaccines for pneumonia (pneumococ-
ci), meningitis (meningococci) and 
Haemophilus influenzae type b. Chil-
dren in Germany are now routinely 
vaccinated against all three pathogens. 
Until now, the glycans have been pro-
duced from cultivated bacteria, which 
makes production complicated and in 
many cases impossible. In the future, 
Seeberger wants to produce vaccines by 
completely chemical means. This will 
also make it possible to manufacture 
new vaccines against bacteria that can’t 
be grown artificially or whose sugars 
can’t be isolated.
His plan is to artificially produce a 
glycan from the surface of the patho-
gen and administer it to lab animals, 
whose immune system will then form 
antibodies against it. However, a pure 
sugar vaccine won’t work, because the 
immune system of children under two 
years of age and people over 55 doesn’t 
recognize it as foreign. 
An auxiliary substance, an adju-
vant, is required to spur on the im-
mune system. To date, exogenous car-
rier proteins such as the diphtheria or 
tetanus toxin have been used for this. 
But not only do they sometimes trig-
ger strong vaccination reactions, they 
are also partly responsible for the high 
price. This is because proteins are sen-
sitive to heat. “More than half of the 
vaccination costs are swallowed up by 
the cold chain. This is a huge problem 
in Africa and Asia.” Coupling the gly-
can to a certain lipid molecule, in-
left-hand page: Left: Peter H. Seeberger heads a large team of several dozen scientists in Potsdam. Right: Daniel Kolarich (standing) 
investigates the role of glycoproteins, Daniel Varón Silva (third from right) works on GPI anchor glycans, Chakkumkal Anish (second from right) 
studies the glyco-biology of infectious diseases, and Bernd Lepenies (far right) analyzes the function of glycan receptors of the immune system.
below: Left: Automated sugar synthesis: The synthesizer brings the reactants together at the right time and in the right quantity. 

































































laboratory animals vaccinated with it 
formed antibodies against all four sero-
types at once.
ONE PATHOGEN, MANY VARIANTS 
Streptococcus pneumoniae isn’t easy to 
fight with a single vaccination, either. 
The pathogen causes middle ear infec-
tions and, in serious cases, can settle in 
the brain or lungs. Tens of thousands of 
children used to die from it every year. 
The vaccine available today contains 13 
different glycans. “Unfortunately, the 
pathogen has 96 different serotypes, 
with a correspondingly large number of 
sugars. The vaccine is therefore not ef-
ficacious for all infections,” explains 
Seeberger. “For two years, ten scientists 
have been working intensively with 
this pathogen, and are learning a great 
deal in the process: some sugar build-
ing blocks are essential, and others can 
be left out.” 
Tests for diagnosing disease are another 
of Seeberger’s research fields. They react 
to the immune system’s antibodies 
against bacteria or viruses. The research-
ers have developed a method for detect-
ing infections with the Toxoplasma gon-
dii parasite, for example. This parasite is 
transmitted by cats and is widespread 
throughout the population, but it is 
dangerous only to pregnant women and 
people with a weak immune system, for 
example following cancer therapy. 
With glycan tests, it’s possible not 
only to determine whether a person is 
infected with a certain germ, but also 
whether they have ever come into con-
tact with it. Even with those that could 
be used as a weapon. The group has 
therefore also developed diagnostic 
methods for potential biological weap-
ons such as anthrax and the plague ba-
cillus Yersinia pestis. 
There is room for up to 10,000 dif-
ferent sugars on small glass chips. “One 
stead, solves both problems in one go. 
An adjuvant is then unnecessary, and 
neither fat nor sugar is heat sensitive. 
Glycolipids are therefore currently the 
hottest candidates for fully synthetic 
vaccines. 
Seeberger’s team is working on vac-
cinations for different diseases, among 
them the tropical diseases Leishmania-
sis and malaria, and for Neisseria men-
ingitidis – bacteria that cause meningi-
tis particularly in newly industrialized 
countries. There are four variants, or se-
rotypes, of Neisseria, and there is an in-
dividual vaccine for each one of them. 
The problem is that serotype B con-
tains a glycan that is also found in the 
brain. Vaccinating someone against 
this sugar could trigger an auto-im-
mune disease. But a vaccine against 
part of it – the so-called endotoxin lip-
id A – possibly would not. To this end, 
Seeberger’s team synthesized a tetrasac-
charide chain in the lab. And indeed: 
above: Left: In flow synthesis, the chemical reactions take place in coiled microreactors. Temperatures of up to 250 degrees Celsius can be achieved 
in a high-temperature reactor (on the right of the photo). Center: Automated glycan array printer for disease diagnosis: The instrument coats glass 
chips with thousands of sugar molecules from pathogens. Right: Analytical instruments can read out the reaction patterns on the glass chips and tell 
Chakkumkal Anish whether somebody has formed antibodies against a pathogen.
below: Principle of a glycan chip: An antibody of a patient (yellow) binds to a sugar molecule on the chip (triangle). It is then coupled to a protein 
(blue) that has been tagged with a fluorescent dye (star). A photo analysis shows the location of the fluorescent signal and thus the binding partner 
of the antibody. The researcher can thus conclude which antibody it is.

















milligram of glycan can coat thousands 
of chips,” says Seeberger. He was the 
first to print the sugars onto the chips 
with a converted inkjet printer. The test 
itself is then very simple: put a drop of 
blood on it, rinse and stain – that’s all 
there is to it. Antibodies in the blood 
sample now bind to the corresponding 
sugar molecules and fluorescent pro-
teins cause them to luminesce. Finally, 
the pattern of light spots reveals the an-
tibody and thus the pathogen. 
Other tests are intended to differen-
tiate between healthy cells and cancer 
cells. Daniel Kolarich from Peter See-
berger’s group discovered that healthy 
skin cells have different glycans on 
their surface than do tumor cells. He is 
now working with dermatologists from 
Leipzig on a test for malignant skin 
cancer cells.
Researchers around the world now 
use Seeberger’s sugar library, which 
now contains more than 600 different 
glycans: neurologists from Zurich are 
using glycans to reduce the effects of 
strokes, and doctors at the Charité hos-
pital in Berlin trace cancer cells with ra-
dioactively labeled sugars. 
The pharmaceutical industry initial-
ly showed little interest in glycomics, 
as Seeberger was forced to realize when 
he was working on the development of 
a vaccine against malaria. In 2002, it 
was successfully proven that a glycan is 
a long-sought toxin of the malaria 
pathogen. “When we synthesized it 
and used it to vaccinate mice, three out 
of four mice survived a subsequent ma-
laria infection.” 
In animal tests, they were able to in-
crease the effectiveness of the further 
improved vaccine candidate to almost 
100 percent. The technology to pro-
duce the vaccine in large quantities was 
also available. Yet the vaccine has been 
put on ice since 2007 because the par-
ticipating companies felt that the risk 
of not recouping the enormous devel-
opment costs was too high. “Industry 
funds primarily projects on illnesses 
that occur in industrialized nations, be-
cause those are the ones that will later 
earn them good money. Hardly any 
profit can be expected from patients in 
poorer countries,” says Seeberger.
But a malaria vaccine is so desper-
ately needed. Just recently, the vaccine 
candidate developed by GlaxoSmith-
Kline with several hundred million eu-
ros of funding from the Bill & Melinda 
Gates Foundation had to be aban-
doned. After several years of develop-
ment, the vaccine turned out to be not 
effective enough.
The consequence is that, some-
where in the world, a child dies of ma-
laria every 20 seconds. But Seeberger 
calculated that only 4.5 kilograms of 
glycan would be required to vaccinate 
 
TO THE POINT
O  Scientists today can produce polysaccharides artificially. They do this by attaching 
the individual sugar building blocks to each other in an arbitrary sequence via 
different binding sites. 
O  Proteins, fats and other cell molecules often have chains of sugar molecules. 
These molecules, called glycans, are important signals for cell communication and 
for the immune system.
O  Glycans are important target molecules for more effective and lower-cost drugs, 
vaccines and diagnostic tests.
the 65 million children born every year 
in malaria-endemic areas. “A vaccina-
tion would cost only a few cents per 
child.” Despite everything, he has not 
given up on the vaccine, and is cam-
paigning for new funding to develop it 
further.
Peter Seeberger doesn’t see himself 
as a do-gooder, but more as a toolmak-
er. “If we have the knowledge and the 
technology to change something, we 
should do it.” But funding isn’t avail-
able for him to undertake clinical stud-
ies himself, nor is this compatible with 
the role of the Max Planck Society. But 
bringing research results as close as pos-
sible to the market is. 
A few companies have already 
emerged from the research in Seeberg-
er’s department. One of them is called 
GlycoUniverse. Doesn’t the name stir 
up overly large expectations? Peter See-
berger laughs. “No, because the compa-
ny produces the sugars as tools that will 
be indispensable for many applications 
in the future.” So there are sweet hopes 
for better medicine for people all over 
the world.  
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